Summit Therapeutics Ownership & Insider Activity

Summit Therapeutics (SMMT) institutional and insider ownership, recent insider transactions and ownership breakdown.

Insiders own 28.5% of shares outstanding. Institutional investors hold 7.1%. Over the past 90 days, insiders made 5 purchases worth $103.6M.

Shares Outstanding

797.750M

Shares Float

156.463M

Insider Shares Owned

220.960M

Insider % Owned

28.5%

Institutional Shares Held

56.953M

Institutional % Held

7.1%

Ownership Breakdown

Net Insider Activity by Month

Purchases (90d)

$103.6M total

Sales (90d)

Net Activity

Net Buying

Net Value (90d)

$103.6M

Summit Therapeutics Insider Transactions (Last 6 Months)

Date	Insider	Title	Type	Shares	Price	Value
Jun 12, 2026	Mahkam Zanganeh	CO-CHIEF EXECUTIVE OFFICER	BUY	3.810M	$13.12	$50.0M
Jun 12, 2026	Robert W Duggan	CO-CHIEF EXECUTIVE OFFICER	BUY	3.810M	$13.12	$50.0M
Jun 4, 2026	Robert W Duggan	CO-CHIEF EXECUTIVE OFFICER	BUY	100.000K	$14.60	$1.5M
Jun 4, 2026	Mahkam Zanganeh	CO-CHIEF EXECUTIVE OFFICER	BUY	100.000K	$14.60	$1.5M
Jun 4, 2026	Manmeet Soni	COO AND CFO	BUY	50.000K	$14.45	$722K

More with Benzinga EdgeGet Access

Summit Therapeutics Inc

Summit Therapeutics Ownership & Insider Activity

Summit Therapeutics Insider Transactions (Last 6 Months)

People Also Watch

뉴스

파트너 / 기고자

벤징가 글로벌

People Also Watch